-
Mashup Score: 1
FDA approves combination treatment for advanced non-small cell lung cancer (NSCLC) targeting specific EGFR mutations. Learn about the MARIPOSA trial results,…
Source: www.youtube.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES - 2 month(s) ago
FDA approved pembrolizumab (Keytruda) combined with chemotherapy for mesothelioma treatment. A new option for patients battling this aggressive disease.
Source: oncologytube.comCategories: General Medicine News, Oncologists1Tweet-
VIDEO: FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma https://t.co/B4eRbWbTNC @Merk @FDAOncology #Immunotherapy #LungCancer #Oncology
-
-
Mashup Score: 0
FDA approves Kisqali for early high-risk breast cancer treatment. Learn about this new treatment option and its benefits for patients.
Source: oncologytube.comCategories: General Medicine News, Oncologists1Tweet-
VIDEO & SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer #ESMO24 https://t.co/vdYvFHbPxp @FDAOncology @Novartis @BreastCancerNow @CancerResrchUK @AmericanCancer @OncoAlert @NovartisNews #Kisqali #Ribociclib #BreastCancer #FDAApproval #CancerResearch… https://t.co/WakeJiZUOB
-
-
Mashup Score: 0
Download Slides: https://oncologytube.com/slides-fda-approves-kisqali-ribociclib-for-early-high-risk-breast-cancer/The FDA has approved Kisqali (ribociclib) …
Source: www.youtube.comCategories: General Medicine News, Oncologists1Tweet-
@FDAOncology SLIDES & VIDEO: FDA Approves Kisqali / Ribociclib for Early High-Risk FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer ESMO 2024 https://t.co/syl2XGnCPN
-
-
Mashup Score: 1VIDEO: iTeos and GSK's TIGIT Combination Therapy Shows Significant Promise at ESMO 2024 - 2 month(s) ago
Promising results from the TIGIT combination therapy trial presented at ESMO 2024. Discover the potential of this treatment for lung cancer.
Source: oncologytube.comCategories: General Medicine News, Oncologists1Tweet-
VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024 https://t.co/Tnzjw0hQ4P #ESMO24 #iTeos #GSK #TIGITtherapy #NSCLC #lungcancer #ESMO2024 #belrestotug #dostarlimab #Jemperli #tumorshrinkage #immunotherapy #PDL1 #checkpointinhibitors… https://t.co/b3Xi5zz0GB https://t.co/5EZVLL0dWY
-
-
Mashup Score: 0FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-L1 Cancer Immunotherapy in NSCLC - 2 month(s) ago
In this video, we explore the FDA approval of Genentech’s Tecentriq Hybreza, the first subcutaneous anti-PD-(L)1 immunotherapy for cancer. Approved on Septem…
Source: www.youtube.comCategories: General Medicine News, Oncologists1Tweet-
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-L1 Cancer Immunotherapy in #NSCLC https://t.co/L57V0c5Q6x @FDAOncology @genentech #Immunotherapy https://t.co/kvv42OEOZ8
-
-
Mashup Score: 0Nivolumab Combo Phase 3 TiNivo 2 Results + Tivozanib in RCC Presented at ESMO 2024: AVEO – OncologyTube - 2 month(s) ago
AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17. The oral presentation will provide key results from the TiNivo-2 clinical trial, which evaluated the efficacy and safety of combining nivolumab, a PD-1 checkpoint inhibitor, with FOTIVDA® (tivozanib), a VEGFR tyrosine kinase inhibitor (TKI). The
Source: oncologytube.comCategories: General Medicine News, Oncologists1Tweet-
Nivolumab Combo Phase 3 TiNivo 2 Results + Tivozanib in RCC Presented at ESMO 2024 by Toni Choueiri https://t.co/nYBIQtxA7o @AVEOOncology #ESMO24 @DanaFarber https://t.co/c54263UPML
-
-
Mashup Score: 5Breast Cancer Genetic Testing - Should Doctors Use ctDNA? Nathalie McDowell Johnson, MD - 3 month(s) ago
Dr. Nathalie M. Johnson, MD, discusses the importance of adopting ctDNA testing in breast cancer management. Find out how it can benefit patients with high-risk breast cancer types.
Source: oncologytube.comCategories: General Medicine News, Oncologists1Tweet-
📺 VIDEO: Breast Cancer Genetic Testing - When Should Doctors Use ctDNA? Nathalie McDowell Johnson, MD https://t.co/7avdfzcWLq @OurLegacyHealth @ASBrS #ASBRS24 @NateraGenetics #BreastCancer #Oncology #ctDNA #DrNathalieJohnson #CancerResearch #TripleNegativeBreastCancer… https://t.co/kREqTXqgne https://t.co/QlpEDmeGkn
-
-
Mashup Score: 2
Exciting news in endometrial cancer treatment: FDA approves dostarlimab-gxly for broader patient population. Learn about the clinical trial and its positive results.
Source: oncologytube.comCategories: General Medicine News, Oncologists1Tweet-
🔥FDA Alert: FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy https://t.co/IpdsPoh9DQ #EndometrialCancer #Dostarlimab #FDAApproval #Oncology #CancerTreatment #Chemotherapy #GSK #ClinicalTrials #RUBYTrial #Immunotherapy #CancerResearch… https://t.co/8Pnw28FFwK https://t.co/s9Mu44CN3p
-
-
Mashup Score: 2
Discover the problem of underutilization of genetic testing in cancer. Find out how it can lead to missed opportunities for early intervention.
Source: oncologytube.comCategories: General Medicine News, Oncologists1Tweet-
📺 VIDEO: 90% Patients Unaware Of Simple Genetic Test for Cancer - Kevin Hughes, MD @MUSChealth https://t.co/ERRm2iIFrT @ASBrS @NateraGenetics #GeneticTesting #CancerPrevention #Oncology #KevinHughesMD #MUSCHealth #PointOfCareTesting #CancerAwareness #NRDNA #BRCA #LynchSyndrome… https://t.co/CnnfpKlmMY https://t.co/S1fCiV8HkE
-
@Jbauml @JNJInnovMed We made a video on this if you are interested FDA Approves Lazcluze Rybrevant Combo in Advanced NSCLC: Data Revealed https://t.co/BiU40oFR8X